Axios: Biogen pulled Aduhelm paper after JAMA demanded edits

[anonymous]

Biogen recently submitted a paper to JAMA, a top medical research journal, that analyzed results from the clinical trials of its new Alzheimer's drug, Aduhelm.

• However, Biogen later withdrew the paper because JAMA considered rejecting it unless edits were made, Axios' Bob Herman scooped yesterday.

Why it matters: The FDA's decision to approve Aduhelm has been mired in controversy; experts say there simply isn't strong enough data to show the drug works. And it appears medical journal reviewers also weren't sold on Biogen's interpretation of the data.

How it works: Drug companies almost always publish clinical trial results in a peer-reviewed journal before obtaining FDA approval, but Biogen still hasn't done so for Aduhelm.

• Biogen executives said during a conference call last week the company was working to get Aduhelm's phase 3 results published in a peer-reviewed journal.

When Axios asked about Biogen's submission to JAMA, the company declined to answer questions beyond saying: "JAMA did not reject the publication. Biogen withdrew the publication from JAMA and decided to pursue other publication opportunities."

Go deeper.

 

[anonymous]

Is Field & Stream magazine accepting articles for publication?

 

[anonymous]

Will Thacker from Horse and Hound Magazine said they’ll publish the data.

 

[anonymous]

Will Thacker from Horse and Hound Magazine said they’ll publish the data.

Very few Notting Hill references on here. Well played.

 

[anonymous]

Very few Notting Hill references on here. Well played.

I know nothing about Notting Hill, so that one flew right over my head. But I absolutely respect a good obscure reference on the message boards.

A tip of the cap to the Will Whacker poster.